Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid Carcinoma
Most Cited Paper
in Cancer-related Molecular Pathways
18 Months Post-Publication
Class of 2026
“Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid Carcinoma”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
BRAF V600E mutation · Anaplastic thyroid carcinoma · dabrafenib · trametinib · pembrolizumab · immune checkpoint inhibitors · anti-PD-1 inhibitor · spartalizumab · BRAF/MEK inhibitors · neoadjuvant therapy · overall survival · progression-free survival · Drug resistance · immune-related adverse events · combination immunotherapy · hepatitis · colitis
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459